This is a working overview of lyophilized powder, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-26 and is reviewed periodically as new material appears.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
He later co-founded the Trinity Broadcasting Network with Paul and Jan Crouch, but left after a short partnership due to disagreements, eventually establishing his own ministry, PTL (Praise The Lord), and the PTL Satellite Network. Returning to televangelism in 2003, Bakker now hosts The Jim Bakker Show with a focus on apocalyptic themes and survivalist products, while distancing himself from his earlier prosperity gospel teachings. His later years have included controversial claims, such as predicting major events and promoting unproven supplements, which drew legal action and criticism during the COVID-19 pandemic. Bakker has written several books, including I Was Wrong and Time Has Come: How to Prepare Now for Epic Events Ahead.
== History == Shotgun proteomics arose from the difficulties of using previous technologies to separate complex mixtures. In 1975, two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) was described by O’Farrell and Klose with the ability to resolve complex protein mixtures. The development of matrix-assisted laser desorption ionization (MALDI), electrospray ionization (ESI), and database searching continued to grow the field of proteomics. However these methods still had difficulty identifying and separating low-abundance proteins, aberrant proteins, and membrane proteins. Shotgun proteomics emerged as a method that could resolve even these proteins.
== Early life and education == Ochoa was born in Luarca (Asturias), Spain. His father was Severo Manuel Ochoa (who he was named after), a lawyer and businessman, and his mother was Carmen de Albornoz. Ochoa was the nephew of Álvaro de Albornoz (President of the Second Spanish Republic in exile and former Foreign Minister), and a cousin of the poet and critic Aurora de Albornoz. His father died when Ochoa was seven, and he and his mother moved to Málaga, where he attended elementary school through high school. His interest in biology was stimulated by the publications of the Spanish neurologist and Nobel laureate Santiago Ramón y Cajal. In 1923, he went to the University of Madrid Medical School, where he hoped to work with Ramón y Cajal, but Ramón y Cajal retired. He studied with father Pedro Arrupe, and Juan Negrín was his teacher:
Sources: en.wikipedia.org
Denazification was an Allied initiative to rid German politics, judiciary, society, culture, press and economy of Nazi ideology and personnel following the Second World War. It was carried out by removing those who had been Nazi Party or SS members from positions of power and influence, by disbanding the organisations associated with Nazism, and by trying prominent Nazis for war crimes. The program was hugely unpopular in West Germany and was opposed by the new government of Konrad Adenauer. In 1951, several laws were passed granting amnesties and ending denazification. As a result, many people with a former Nazi past ended up again in the political apparatus of West Germany. Between 1951 and 1953, there was even an effort by a clandestine group of former Nazi functionaries, known as the Naumann Circle, to infiltrate the Free Democratic Party (FDP) in order to lay the groundwork for an eventual return to power. Although this effort was exposed and disrupted, many former Nazis still attained positions of power and influence in the political system. West German President (1974–1979) Walter Scheel and Chancellor (1966–1969) Kurt Georg Kiesinger were both former members of the Nazi Party. Konrad Adenauer's State Secretary Hans Globke had played a major role in drafting the antisemitic Nuremberg Race Laws in Nazi Germany. In 1957, 77% of the West German Ministry of Justice's senior officials were former Nazi Party members.
==== MeSH D12.776.835.725.868 – eukaryotic initiation factors ==== MeSH D12.776.835.725.868.124 – eukaryotic initiation factor-1 MeSH D12.776.835.725.868.249 – eukaryotic initiation factor-2 MeSH D12.776.835.725.868.374 – eukaryotic initiation factor-2b MeSH D12.776.835.725.868.437 – eukaryotic initiation factor 3 MeSH D12.776.835.725.868.500 – eukaryotic initiation factor-4f MeSH D12.776.835.725.868.500.500 – eukaryotic initiation factor-4a MeSH D12.776.835.725.868.500.750 – eukaryotic initiation factor-4e MeSH D12.776.835.725.868.500.875 – Eukaryotic initiation factor 4G MeSH D12.776.835.725.868.750 – eukaryotic initiation factor-5
Fentanyl and fentanyl analogues can be qualitatively detected in drug samples using commercially available fentanyl testing strips or spot reagents. Following the principles of harm reduction, this test is to be used directly on drug samples as opposed to urine. To prepare a sample for testing, approximately 10 mg of the drug should be diluted into 1 tsp (5 mL) of water. Research in Dr. Lieberman's lab at the University of Notre Dame has reported false positive results on BTNX fentanyl testing strips with methamphetamine, MDMA, and diphenhydramine. The sensitivity and specificity of fentanyl test strips vary depending on the concentration of fentanyl tested, particularly from 10 to 250 ng/mL.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.